Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901

NCT04695652 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT04695652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04695652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Double-blinded, Multi-Center, Multi-Regional Study to Evaluate the Safety, Tolerability, and Immunogenicity of the SARS-CoV-2 Vaccine Candidate MVC-COV1901
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 2
Overall status
Completed
Start date
December 30, 2020
Completion date
October 29, 2021
Enrollment
3,854 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 vaccine